

Special Issue

Frontiers in Vaccines for COVID-19 and Related Coronavirus Diseases

Message from the Guest Editor

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) has been identified as the causative agent of Coronavirus Disease 2019 (COVID-19). The virus was first reported in Wuhan, China, and subsequently rapidly spread around the world, leading to one of the most severe pandemics in human history. By January 2021, more than 94 million confirmed cases have been reported in 191 countries and territories, and more than 2,029 million people have died. Worldwide efforts to stop transmission of SARS-CoV-2 and end the pandemic did not succeed in eradicating the virus, yet. Therefore, the development of effective intervention and prevention strategies is of uttermost importance. This Special Issue focuses on the following aspects: 1. Development of vaccines against COVID-19 and other coronaviruses 2. Factors influencing vaccine performance and outcome (e.g. environmental, comorbidities, gender). Dr. Sarah R. Leist

Guest Editor

Dr. Sarah R. Leist

Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA

Deadline for manuscript submissions

closed (31 May 2022)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/74815

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).